Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Lorenz Oelschläger, Deedra Nicolet, Krzysztof Mrózek, Daniel Schnell, Najla Alotaibi, Christopher J. Walker, Alice Mims, James S. Blachly, Bayard L Powell, Jonathan E Kolitz, Eunice S. Wang, Andrew J. Carroll, Lynn van Rosmalen, Bettina Nadorp, Nathan Salomonis, H. Leighton Grimes, Maarten Fornerod, Ann-Kathrin Eisfeld

Blood (2024) 144 (Supplement 1): 641.

https://doi.org/10.1182/blood-2024-210423

Published: 2024

Journal Articles

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

Daniel T Peters, Deedra Nicolet, Yazan F Madanat, Jesus D Gonzalez-Lugo, Alexander J. Ambinder, Onyee Chan, Michael Jamie Hochman, Najla H. Al Ali, Victoria Klein, Krzysztof Mrózek, Tara L. Lin, Alice Mims, Charles Foucar, Joshua F Zeidner

Blood (2024) 144 (Supplement 1): 324.

https://doi.org/10.1182/blood-2024-193667

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2024) 144 (Supplement 1): 2907.2.

https://doi.org/10.1182/blood-2024-210967

Published: 2024

Journal Articles

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Areej El-Jawahri, Alison R Kavanaugh, Joseph A Greer, Vicki Jackson, Jillian Gustin, Alice Mims, Albert Cook, Thomas W. LeBlanc, Amir T. Fathi, Gabriela S. Hobbs, Andrew M. Brunner, Jennifer S Temel

Blood (2024) 144 (Supplement 1): 117.

https://doi.org/10.1182/blood-2024-209628

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch

Melanie T Rebechi, Quihong Zhao, Michael Marcucci, Nidhi Sharma, Allyson Waller, Marvellous Olowookere, Alyssa Swank, Christian Hu, Alice Mims, Jennifer E. Vaughn

Blood (2024) 144 (Supplement 1): 1771.

https://doi.org/10.1182/blood-2024-203869

Published: 2024

Journal Articles

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

Blood (2024) 144 (Supplement 1): 7303.

https://doi.org/10.1182/blood-2024-194146

Published: 2024

Journal Articles

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 7309.

https://doi.org/10.1182/blood-2024-202650

Published: 2024

Journal Articles

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Eytan M. Stein, Leora Boussi, Alice Mims, Justin M. Watts, Gabriel N Mannis, Hongtao Liu, David Sallman, Farhad Ravandi, Gary J. Schiller, Eunice S. Wang, Brian J. Ball, J. Jean Cui, Jihao Zhou, Armin Graber, Zachary Zimmerman, Stephen Anthony Strickland

Blood (2024) 144 (Supplement 1): 5998.

https://doi.org/10.1182/blood-2024-204046

Published: 2024

Journal Articles

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Andrea Laganson, Victoria Klein, Deedra Nicolet, Aadarsh Teli, Krzysztof Mrózek, Jacob Wareti, Michael C Walker, Christopher Manring, James L Fisher, Electra D Paskett, Elizabeth Ghias, Jesse J Plascak, Alice Mims, Ann-Kathrin Eisfeld, Jill Buss

Blood (2024) 144 (Supplement 1): 7921.

https://doi.org/10.1182/blood-2024-211563

Published: 2024

Journal Articles

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

Kelly Pugh, Michael C Walker, Deedra Nicolet, Victoria Klein, Krzysztof Mrózek, Gregory K Behbehani, James S. Blachly, Uma Borate, Nicole R. Grieselhuber, Kristin L Koenig, Karilyn T. Larkin, Meixiao Long, Andrew Srisuwananukorn, Ann-Kathrin Eisfeld, Alice Mims

Blood (2024) 144 (Supplement 1): 7929.

https://doi.org/10.1182/blood-2024-210135

Published: 2024

Journal Articles

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Blood (2024) 144 (Supplement 1): 4184.

https://doi.org/10.1182/blood-2024-205812

Published: 2024

Journal Articles

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

Guillermo Garcia-Manero, David Sallman, Stefano R Tarantolo, Amit Verma, Stefanie Groepper, Alice Mims, Yasmin Abaza, James P. Dugan, Valle Gomez G De Soria, Gaurav S Choudhary, Maureen Lane, Wanying Zhao, Ashish Jain, Cole Gallagher, Uwe Platzbecker

Blood (2024) 144 (Supplement 1): 3225.

https://doi.org/10.1182/blood-2024-208292

Published: 2024

Journal Articles

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Uma Borate, Kaitlyn M. Dvorak-Kornaus, Qiuhong Zhao, Roland B. Walter, Rachel J. Cook, Jennifer N. Saultz, Ronan T. Swords, Nicole R. Grieselhuber, Alice Mims, Karilyn T. Larkin, Kieran D Sahasrabudhe, James S. Blachly, Gregory K Behbehani, Ann-Kathrin Eisfeld, Meixiao Long, Andrew Srisuwananukorn, Kristin L Koenig

Blood (2024) 144 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2024-210605

Published: 2024

Journal Articles

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2432.

https://doi.org/10.1182/blood-2024-203704

Published: 2024

Journal Articles

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Blood (2024) 144 (Supplement 1): 2426.

https://doi.org/10.1182/blood-2024-207278

Published: 2024

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2883.4.

https://doi.org/10.1182/blood-2024-208822

Published: 2024

Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Blood (2024) 144 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2024-202596

Published: 2024

Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Blood (2024) 144 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2024-211178

Published: 2024

Journal Articles

Understanding Valuation of Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia Using a Novel Hypothetical Purchasing Task

Jennifer E. Vaughn, Quihong Zhao, Michael Marcucci, Nidhi Sharma, Alice Mims, Allyson Waller, Jeff Stein

Blood (2024) 144 (Supplement 1): 5049.

https://doi.org/10.1182/blood-2024-203641

Published: 2024

NARROW

Transcriptomically Defined Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) Phenotype Governs Mutation-Based Disease Group Assignment

Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Multi-Site Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Receiving Non-Intensive Therapy

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Comparison of Long-Term Outcomes Among Patients with Chronic Myeloid Leukemia Who Undergo Initial Tyrosine Kinase Inhibitor Dose Reduction Versus Tyrosine Kinase Inhibitor Switch

Comparison of Two Myeloablative Total-Body Irradiation (MAC-TBI) Regimens: 1200 Cgy Vs 800 Cgy of TBI for Allogeneic Stem Cell Transplantation in Adults with Hematological Malignancies

GATA2 -Mutated AML: Clinical Outcomes and Spectrum of Infections in Patients Undergoing or Not Allogeneic Stem Cell Transplantation

A Phase 1/1b Open-Label, Dose Escalation, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Leukemic Activity of the Orally Available CDC-like Kinase Inhibitor, BH-30236, in Adults with R/R AML or HR-MDS

Impact of Socioeconomic Factors on Survival for Adolescent and Young Adult (AYA) Patients (Pts) with Acute Myeloid Leukemia

Real World Outcomes of Patients (Pts) with Acute Myeloid Leukemia, Myelodysplasia-Related (AML-MR) or Therapy-Related AML (t-AML) Receiving Venetoclax-Based Therapies

The Incidence of CNS Relapse in Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) and Its Impact on Clinical Outcome: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Preliminary Safety, Efficacy and Molecular Characterization in Patients with Higher-Risk Myelodysplastic Syndrome Treated with Single Agent Emavusertib (CA-4948)

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination with Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia

Real-World Experience of Venetoclax Target Dosing with Concomitant Posaconazole in Adult Patients with Acute Myeloid Leukemia

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Understanding Valuation of Tyrosine Kinase Inhibitors Among Patients with Chronic Myeloid Leukemia Using a Novel Hypothetical Purchasing Task

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only